UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/566,369	01/30/2006	Oleg Naigertsik	1268-254 2102	
	7590 01/03/201 MAN HAM & BERN	EXAMINER		
1700 DIAGON SUITE 300		TRAN, THAO T		
ALEXANDRIA, VA 22314			ART UNIT	PAPER NUMBER
			1787	
		MAIL DATE	DELIVERY MODE	
			01/03/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summany		Application	ı No.	Applicant(s)				
		10/566,369)	NAIGERTSIK ET AL.				
	Office Action Summary	Examiner		Art Unit				
		Thao T. Tra		1787				
Period ¹	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1) 🔀	Responsive to communication(s) filed on 18 Oc	ctober 2010						
•	This action is FINAL . 2b) ☐ This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
٠,١	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
	·		, , ,					
Disposi	tion of Claims							
4)	4) Claim(s) See Continuation Sheet is/are pending in the application.							
	4a) Of the above claim(s) See Continuation Sheet is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.							
6)🗵	6)⊠ Claim(s) <u>1,9,10,13,15,17,19,22-24 and 29</u> is/are rejected.							
7)	Claim(s) is/are objected to.							
8)	Claim(s) are subject to restriction and/or	r election red	quirement.					
Application Papers								
9)[The specification is objected to by the Examine	r.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
	Replacement drawing sheet(s) including the correcti	ion is required	d if the drawing(s) is obj	ected to. See 37 CI	FR 1.121(d).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
2)	nt(s) ice of References Cited (PTO-892) ice of Draftsperson's Patent Drawing Review (PTO-948) irmation Disclosure Statement(s) (PTO/SB/08) irm No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te				

Continuation of Disposition of Claims: Claims pending in the application are 1,9,10,13,15,17,19,22-24,29,33,40-43,45,47,48,51,52,56,60,62,73,74,82,83,86,88,90,92 and 94-97.

Continuation of Disposition of Claims: Claims withdrawn from consideration are 33,40-43,45,47,48,51,52,56,60-62,73,74,82,83,86,90,92 and 94-97.

Application/Control Number: 10/566,369 Page 2

Art Unit: 1787

DETAILED ACTION

- 1. This is in response to the Amendment filed on 10/18/2010.
- 2. Claims 1, 9-10, 13, 15, 17, 19, 22-24, 29, 33, 40-43, 45, 47-48, 51-52, 56, 60, 62, 73-74, 82-83, 86, 88, 90, 92, 94-97 are currently pending in this application.
- 3. This application contains claims 33, 40-43, 45, 47, 48, 51-52, 56, 60-62, 73-74, 82-83, 86, 90, 92, 94-97 drawn to an invention nonelected with traverse in the reply filed on 1/25/2010. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.
- 4. In view of the Amendment, the previous claim objection has been withdrawn. However, the 103 rejection is set forth below.

Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. Claims 1, 9-10, 13, 15, 17, 19, 22-24, and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lapidot et al. (US 2002/0064541).

Lapidot discloses a composition, comprising microcapsules having a core-shell structure. The core of each microcapsule includes at least one active ingredient and is encapsulated within a microcapsular shell; whereas the shell is comprised of at least one inorganic polymer obtained by a sol-gel (in-situ) process (see abstract).

Art Unit: 1787

The active ingredients include antibiotics, anti-fungal agents, anti-inflammatory agents, perfumes, colors, dyes, enzymes, vitamins, or mixture thereof (see claims 1-89). Example 8 shows the active ingredient to be octylmethoxy cinnamate, a sunscreen compound [0264]. Example 7 shows the active ingredient to be azo dye Congo Red, which is a fluorescent dye [0253].

The inorganic polymer is prepared from a sol-gel precursor, such as a metal alkoxide monomer [0131]. Example 1 shows the monomer used to be tetraethoxy silane [0243].

The composition further comprises a carrier [0032].

With respect to the amount of the active ingredient material in the core and the pH used, Lapidot teaches about 1% to about 95% [0095] and a pH of 7.4 (Example 8). Thus, by teaching about 95%, Lapidot directly the presently claimed range. And a pH of 7.4 is approximate the presently claimed range. Thus, the presently claimed invention would be considered obvious over the Lapidot reference, absence of evidence to the contrary.

Response to Arguments

7. Applicant's arguments filed 10/18/2010 have been fully considered but they are not persuasive.

Throughout the Remark, Applicants argue that Lapidot does not teach the presently claimed amount of the core material or the pH. However, as mentioned above, Lapidot discloses a core material amount of about 95%, thus obvious over the presently claimed amount of 96%. Lapidot also teaches a pH of 7.4, approximate the presently claimed pH of 7.0. Thus, the presently claimed invention would be considered obvious over the reference of Lapidot.

Application/Control Number: 10/566,369 Page 4

Art Unit: 1787

Conclusion

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thao T. Tran whose telephone number is 571-272-1080. The examiner can normally be reached on Monday-Friday, from 9:00 a.m. - 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Callie Shosho can be reached on 571-272-1123. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/566,369 Page 5

Art Unit: 1787

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Thao T. Tran/ Primary Examiner, Art Unit 1787

tt